Investor
The gastrointestinal surgery-focused company will use the funds to advance its endoluminal robotics technology for minimally invasive procedures.
The funds will be used to develop a comprehensive AI imaging model powered by imaging data to improve diagnostic precisions and early detection of conditions.
The company's product, Distill, uses machine learning algorithms and LLMs to perform administrative, clinical and research tasks that require chart review.
The company will use the funds to grow its drug-discovery pipeline and clinical AI stack.
The healthcare system became a strategic investor in the Boston-based company and will utilize Laudio to enhance worker efficiency and engagement.
The digital therapeutics company and virtual chronic pain-management program will combine their offerings to create a digital care-management solution for chronic pain.
The company will use the funds to expand the reach of its sepsis-focused diagnostic test, IntelliSep.
Also, H2U has received strategic investment to take on the South Korean market.
It has also obtained its third US FDA 510(k) clearance.